The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study

BACKGROUND: Nab-paclitaxel plus gemcitabine (AG) and modified FOLFIRINOX (FFX) are two systemic therapies that have been widely used as standard first-line chemotherapy regimens in metastatic pancreatic cancer. However, since there is no clinical trial to directly compare the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lei, Su, Jing, Wang, Wenbo, Zhou, Fuxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869579/
https://www.ncbi.nlm.nih.gov/pubmed/36691032
http://dx.doi.org/10.1186/s12957-023-02896-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869579/
https://www.ncbi.nlm.nih.gov/pubmed/36691032
http://dx.doi.org/10.1186/s12957-023-02896-z

Ejemplares similares